CERO — CERO THERAPEUTICS HOLDINGS, INC.
—
OTC ·
Health Care ·
Biotechnology ·
CIK 1870404 ·
Last close
$0.00
Market Cap
$290.1K
52W High
$0.14
52W Low
$0.00
ADV30
565,356
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -3,846,466 | -1,028,830 | 1,899,971 | 937,512 | 32,405,268 |
| Mar 2026 | 0 | — | -4,845,728 | -5,885,914 | 2,205,110 | 857,489 | 11,463,865 |
| Dec 2025 | 0 | — | -4,426,248 | -4,540,621 | 3,641,134 | 1,662,380 | 9,087,596 |
| Sep 2025 | 0 | — | -4,362,579 | -4,856,395 | 3,911,394 | 2,022,072 | 8,454,556 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-12,100,507
Investing CF
$0
Financing CF
$9,235,345
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-71.71
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-97,752,859
Inventory
—
Receivables
—
ST Investments
$500,000
EBIT TTM
$-14,847,241
Pretax Income TTM
$-16,311,760
Interest Exp TTM
$856,330
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -19,326,699 | -19,920,262 | 3,641,134 | 9,087,596 | -5,446,462 | -16,080,250 |
| Dec 2024 | — | — | — | 6,210,000 | 8,100,000 | -1,894,563 | — |
| Dec 2023 | 0 | -7,675,049 | -7,289,577 | 5,130,000 | 47,183,997 | -42,057,695 | -5,789,987 |
| Dec 2022 | 0 | -11,971,231 | -11,829,116 | 11,300,000 | 46,200,000 | -34,870,780 | -11,709,311 |
| Dec 2021 | 0 | -11,616,331 | -10,629,620 | — | — | — | -10,094,380 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-16,311,760
OpCashFlow TTM
—
Assets (Latest)
$1,899,971
Forward EPS
$-3.26
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SCNI | Scinai Immunotherapeutics Ltd. | $252.4K | $0.37 | — |
| CPMV | Mosaic ImmunoEngineering Inc. | $550.4K | $0.08 | — |
| GPLB | Green Planet Bio Engineering Co. Ltd. | $580.2K | $0.03 | — |
| SLXN | Silexion Therapeutics Corp | $1.07M | $1.65 | — |
| AGTX | Agentix Corp. | $1.35M | $0.03 | — |
News headlines (Yahoo Finance, 1h cache)
CERo Therapeutics Doses 7th Patient in Phase 1 CER-1236 Trial
2026-11-03 13:15 · Yahoo
CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
2026-10-26 21:21 · Yahoo
SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies
2026-10-26 13:05 · Yahoo
CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers
2026-10-26 13:00 · Yahoo
SRX Global and CERO 1236, a Wholly-Owned SPV, Enter into Definitive Agreement to Acquire CERo Therapeutics, an Innovative Cellular Immunotherapy Company Developing CER 1236 for Hematologic Malignancie
2026-10-07 19:00 · Yahoo
SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers
2026-08-31 11:30 · Yahoo
Delisting of Securities from The Nasdaq Stock Market
2026-07-10 16:00 · Yahoo
CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-03-30 12:15 · Yahoo
CERo Therapeutics Announces Clinical Update from CERTAIN-T Phase 1 CER-1236 Trial, Including Patient Undergoing Allogeneic Stem Cell Transplant Following Treatment
2026-06-15 12:15 · Yahoo
CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial
2026-04-14 12:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.